Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) MSH3 Antibodies:
anti-Human MSH3 Antibodies:
anti-Mouse (Murine) MSH3 Antibodies:
Go to our pre-filtered search.
Human Monoclonal MSH3 Primary Antibody for IF, WB - ABIN968513
Watanabe, Ikejima, Suzuki, Shimada: Genomic organization and expression of the human MSH3 gene. in Genomics 1997
Show all 4 Pubmed References
Human Polyclonal MSH3 Primary Antibody for ICC, IF - ABIN4335850
Amaral-Silva, Sánchez-Romero, Wagner, Martins, Pontes, Fregnani, Soares, Almeida, Rocha, Santos-Silva, Fonseca, Vargas: Prognostic significance of hMSH2, hMSH3, and hMSH6 expression in ameloblastoma. in Oral surgery, oral medicine, oral pathology and oral radiology 2017
Findings indicate that carriers of the MSH5 (show MSH5 Antibodies) rs707939 T allele, the MSH2 (show MSH2 Antibodies) rs6544991 C allele, the MSH3 rs6151627 and rs6151670 G alleles, and the MSH3 rs7709909 T allele have poor toxicity tolerance to platinum-based chemotherapy in non-small cell lung cancer patients.
MSH3 is probably a modifier of disease progression in Huntington's disease.
data suggest that MSH3 mutations represent an additional recessive subtype of colorectal adenomatous polyposis
Three polymorphisms in MSH3 were associated with variation in somatic instability in myotonic dystrophy type 1.
Our meta-analysis results demonstrated that MSH3 rs26279 G > A polymorphism is associated with an increased risk of overall cancer, especially for the colorectal cancer and breast cancer.
The mismatch-binding protein MutS beta, a heterodimer of MSH2 and MSH3, activates ATR in response to DNA double-strand breaks.
Data show that single nucleotide polymorphisms in MutS homolog 3 (MSH3) had an impact on the chemotherapy response and prognosis of advanced non-small cell lung cancer (NCSLC) patients who were treated with platinum-based chemotherapy.
Our data present, for the first time, evidence that inherited MLH1 (show MLH1 Antibodies) c.-93G>A, MSH2 (show MSH2 Antibodies) c.211 + 9C>G, MSH3 c.3133G>A, and EXO1 (show EXO1 Antibodies) c.1765G>A abnormalities of DNA MMR (show MRC1 Antibodies) pathway are important determinants of head and neck squamous cell carcinoma
IL6 (show IL6 Antibodies) signaling disrupts the nuclear localization of hMSH3 and DNA repair, leading to elevated microsatellite alterations at selected tetranucleotide repeats in cancer cell lines.
Methylation of MSH3 together with exposure to tobacco smoke is involved in esophageal carcinogenesis.
MSH2 (show MSH2 Antibodies)-MSH3 suppresses chromosomal instability and modulates the tumor spectrum in p53 (show TP53 Antibodies)-deficient tumorigenesis.
naturally occurring MSH3 protein polymorphisms are modifiers of CAG repeat (show CELF3 Antibodies) instability, likely through variable MSH3 protein stability
Enhanced occupancy of Msh2 (show MSH2 Antibodies) and Msh3 proteins downstream of the FXN (show FXN Antibodies) expanded GAA (show GAA Antibodies) repeat, suggesting a model in which Msh2 (show MSH2 Antibodies)/3 dimers are recruited to this region to repair mismatches.
Stress treatment of mouse cells with ethanol or hydrogen peroxide caused the re-distribution of MSH3 into nuclear bodies containing the proliferating cell nuclear antigen (PCNA (show PCNA Antibodies)), a known binding partner of MutSbeta.
A (CTG)84 repeat was stable even in Msh3-deficient mice.
Data suggest that MutS homologues Msh2 (show MSH2 Antibodies), Msh3, and Msh6 (show MSH6 Antibodies) play overlapping and distinct roles during antibody diversification processes.
Data suggest that activation-induced cytidine deaminase (show AICDA Antibodies) has limited entry points into V and S regions in vivo, and subsequent mutation requires Msh2 (show MSH2 Antibodies)-Msh6 (show MSH6 Antibodies), but not Msh3, and DNA polymerase (show POLB Antibodies).
Frequencies and patterns in DNA mismatch repair in the context of mice deficient for Msh3.
The protein encoded by this gene forms a heterodimer with MSH2 to form MutS beta, part of the post-replicative DNA mismatch repair system. MutS beta initiates mismatch repair by binding to a mismatch and then forming a complex with MutL alpha heterodimer. This gene contains a polymorphic 9 bp tandem repeat sequence in the first exon. The repeat is present 6 times in the reference genome sequence and 3-7 repeats have been reported. Defects in this gene are a cause of susceptibility to endometrial cancer.
DNA mismatch repair protein Msh3
, DNA mismatch repair protein MSH3
, hypothetical protein
, divergent upstream protein
, mismatch repair protein 1
, protein repair-1
, protein repair-3